Full-Time
Senior / Staff Software Engineer
Computational Chemistry / Molecular Dynamics
Genesis Therapeutics
51-200 employees
AI-driven drug discovery for pharmaceuticals
No salary listed
Senior, Expert
Burlingame, CA, USA
Hybrid
- Experienced working in the fields of computational chemistry and drug discovery
- Experienced writing production code and driving projects to completion
- Comfortable working across all levels of the software stack, building intuitive APIs and libraries for computational chemists
- A deep thinker who reasons from first principles, balances attention to detail with architectural thinking, and has an investigational curiosity to find the root cause of a problem
- Build and maintain complex computational chemistry workflows for drug discovery
- Work closely with computational chemists and CADD scientists to productionize new computational methods for molecular property prediction
- Help scale our data infrastructure to handle billions of datapoints and hundreds of thousands of parallel QM and molecular dynamics jobs
Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech and pharmaceutical companies, exemplified by a significant deal with Eli Lilly. The goal is to discover and develop critical new medicines through its advanced technology.
Company Size
51-200
Company Stage
Series B
Total Funding
$280.1M
Headquarters
Burlingame, California
Founded
2019
Simplify's Take
What believers are saying
- Partnership with NVIDIA enhances AI capabilities for drug discovery.
- $200M Series B funding supports platform and pipeline expansion.
- Named a 'Fierce 15' company, highlighting industry leadership.
What critics are saying
- Competition from AI-driven companies like Insilico Medicine and Exscientia.
- Over-reliance on partnerships may lead to financial instability.
- Regulatory challenges could delay AI-generated drug approvals.
What makes Genesis Therapeutics unique
- Genesis uses 3D spatial graph modeling for novel drug discovery.
- The GEMS platform leverages physics-inspired AI for molecular design.
- Genesis collaborates with major pharma companies like Eli Lilly and Gilead.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -2%2 year growth
↑ 0%Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.
Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.
Genesis Therapeutics receives equity investment from NVIDIA.
Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.